Blue Water Life Science Advisors’s MaxCyte MXCT Stock Holding History

Blue Water Life Science Advisors’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-603,937	Closed	-$2.37M	–	9
2024 Q2	$2.37M	Hold	603,937	–	–	2.3%	8
2024 Q1	$2.53M	Sell	603,937 -1,281,063	-68%	-$6.01M	2.38%	8
2023 Q4	$8.86M	Hold	1,885,000	–	–	7.76%	6
2023 Q3	$5.88M	Hold	1,885,000	–	–	5.55%	6
2023 Q2	$8.65M	Sell	1,885,000 -1,340,000	-42%	-$6.16M	5.84%	6
2023 Q1	$16M	Hold	3,225,000	–	–	10.56%	4
2022 Q4	$17.6M	Hold	3,225,000	–	–	11.83%	5
2022 Q3	$21M	Buy	+3,225,000	New	+$18M	8.46%	7

Other funds holding MXCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Blue Water Life Science Advisors's MXCT Position: Q3 2024 in Review

Blue Water Life Science Advisors sold out of MaxCyte (MXCT) in Q3 2024, closing a stake of 603,937 shares — an estimated $2.37M sold.

Blue Water Life Science Advisors first reported a position in MXCT in Q3 2022 and held it in 8 quarters. The position peaked at $21M in Q3 2022. 120 funds tracked by Wall St. Rank hold MXCT as of Q3 2024.

Blue Water Life Science Advisors reported no remaining MaxCyte position as of Q3 2024 after selling out during the quarter.
Blue Water Life Science Advisors sold 603,937 MaxCyte shares in Q3 2024, an estimated $2.37M.
Blue Water Life Science Advisors first reported a position in MaxCyte in Q3 2022 and held it in 8 quarters.
Blue Water Life Science Advisors's MaxCyte position peaked at $21M in Q3 2022.
120 funds tracked by Wall St. Rank held MaxCyte as of Q3 2024.

Based on Blue Water Life Science Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.